WHERE TO WATCH
MindMed Invests $5 Million in NYU Langone for Psychedelic Research Center
October 8, 2020
Psychedelic medicine company MindMed is investing $5 million in a new research center. J.R Rahn, co-founder and co-CEO of MindMed, discusses the investment and plans to hit the markets.
Builders Say Home Bars Are Hot Items During Coronavirus Lockdowns
Nov 16, 2020
Study: 20% of Covid-19 Patients Later Develop New Mental Illness
According to a recent study, nearly 20% of patients diagnosed with Covid-19 develop a new mental illness such as anxiety or depression within 90 days of their diagnosis. The research looked at the health records of over 62,000 U.S. coronavirus patients. Psychologist Dr. Wilfred Van Gorp joined Wake Up With Cheddar for more.
Oct 9, 2020
MindMed Invests $5 Million in Psychedelic Research Center, Applies to Uplist on Nasdaq
Mindmed has entered a partnership with NYU Langone and will invest $5 million in psychedelic treatments. JR Rahn, Mindmed CEO, joined Cheddar to discuss how the company can help patients suffering from mental health issues and other illnesses like addiction.
Feb 28, 2019
MYnd Analytics Uses A.I. to Help Treat PTSD and Depression
MYnd Analytics is using artificial intelligence to help treat mental health issues like depression and PTSD. Dr. Robin Smith, chairman of the board at MYnd Analytics, explains how it works in this week's Keep Reinventing segment brought to you by HP.